Strata achieved its 13% organic margin target and expects about 60% free cash flow conversion in 2026, while expanding an end-to-end transplant clinical platform through acquisitions and national logistics scale.
SRTA · Strata Critical Medical, Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
Strata Critical Medical reported Q3 2026 revenue of $74.1 million, up 50.3%, adjusted EBITDA of $9.6 million and free cash flow of $8.6 million. It reiterated 2026 guidance and announced a $20 million share repurchase authorization.
Strata Critical Medical reported revenue of $214.0 million for the nine months ended September 30, 2026, up 64.1% from $130.4 million, as Clinical revenue reached $73.2 million and total gross margin increased to 21.6%.
Strata Critical Medical reported Q3 2026 revenue of $74.1 million, up 50.3% year-over-year, and Adjusted EBITDA of $9.6 million. Free Cash Flow was $8.6 million, and the company announced a $20 million share repurchase authorization.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q2 FY26 earnings call · Aug 4, 2026TL;DR. Strata posted Q2 revenue up 60.7% to $72.5M with strong clinical growth, closed three bolt-on acquisitions, and raised 2026 revenue guidance to $285–295M and adjusted EBITDA to $33–35M, while logistics growth and margin softened due to a one-customer volume reduction.
- + Closed three bolt-on acquisitions adding ~$20M revenue and $6.3M projected annualized adjusted EBITDA
- + Adjusted EBITDA margin expanded 140 bps sequentially to 10.9% with $7.9M adjusted EBITDA
- − Logistics gross margin fell to 18.4% from 19.3% sequentially and below ~20% expectation; guided to only 18.5–20% for H2
- − Logistics revenue headwind of ~3% from a non-exclusive customer reducing flying for one organ type
- − Q3 logistics revenue expected to decline high single digits sequentially due to customer reduction and summer seasonality
- − Logistics gross profit declined 1.3% YoY to $8.9M with gross margin down 160 bps to 18.4%
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | 14.3M | six months ended June 30, 2026 | — |
| Adjusted EBITDA as a percentage of revenue non-GAAP | 10.2% | six months ended June 30, 2026 | — |
| Adjusted SG&A non-GAAP | 18.33M | six months ended June 30, 2026 | — |
| Adjusted SG&A as a percentage of Revenue non-GAAP | 12.6% | three months ended June 30, 2026 | — |
| Clinical gross margin | 26.1% | the three months ended June 30, 2026 filing | — |
| Clinical revenue growth excluding Clinical acquisitions completed in Q2 2026 non-GAAP | 15.1% | Q2 2026 vs. Q1 2026 | — |
| Clinical revenue sequential growth | 22.6% | Q2 2026 vs. Q1 2026 | — |
| Free cash flow non-GAAP | 2.88M | Three Months Ended June 30, 2026 | — |
GAAP → non-GAAP reconciliationGAAP Net cash provided by operating activities 5.69M
-314K Capitalized software development costs
-2.49M Purchase of property and equipment, net of proceeds from disposal
= Free cash flow 2.88M
|
|||
| Free Cash Flow, before aircraft and engine acquisitions non-GAAP | 2.9M | Q2 2026 | — |
| Transplant Clinical revenue sequential growth | 23.8% | Q2 2026 vs. Q1 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Care Facilities — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SRTA
this stock
Strata Critical Medical, Inc.
|
$487.45M | +14.6% | +34.3% | — | 5.1% |
|
HCA
HCA Healthcare, Inc.
|
$104.25B | +6.9% | +7.1% | 16.6 | 2.3% |
|
FSNUY
Fresenius SE & Co. KGaA
|
$33.34B | +3.3% | — | — | 0.0% |
|
THC
Tenet Healthcare Corp
|
$22.76B | +43.9% | +0.9% | 8.3 | 2.2% |
|
EHC
Encompass Health Corp
|
$13.83B | +32.8% | +10.5% | 22.0 | 3.7% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 10, 2026
- This year
- 16
Strata achieved its 13% organic margin target and expects about 60% free cash flow conversion in 2026, while expanding an end-to-end transplant clinical platform through acquisitions and national logistics scale.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SRTA | -0.9% | +21.4% | -10.3% | +24.1% | +14.6% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | -3.5% | +22.5% | -10.8% | +24.3% | +3.9% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.